CRIS 10-Q filed 2026-11-13 | Key takeaways
CRIS filed its 10-Q; the most relevant disclosure change is expanded Going concern disclosure: Company concluded there are conditions and events that raise substantial doubt about ability to continue as a going concern within one year after the Condensed Consolidated Financial Statements are issued, based on $5.0 million cash at September 30, 2026, appr.
Key takeaways
Going concern: Company concluded it does not have sufficient cash to fund operations for 12 months from filing date based on $5.0 million cash at September 30, 2026 plus approximately $7.5 million in October 2026 Private Placement proceeds.
Nasdaq delist determination: Received notice on November 2, 2026 that bid price closed below $1.00 for 30 consecutive business days; company appealed and scheduled November 18, 2026 shareholder vote on additional reverse stock split.
Revenue elimination: Revenues fell to zero for both Q3 and nine months 2026 following the November 2025 sale of Erivedge to Oberland Capital; Q3 2025 had $3.2 million and nine months 2025 had $8.3 million in royalty revenues.
Warrant liability changes: January 2026 Series A and C Common Warrants reclassified from liabilities to equity in Q1 2026 resulting in $28.6 million reclassification; change in fair value of warrant liabilities drove $10.9 million loss for nine months 2026.
Stockholder equity declined to $2.6 million as of September 30, 2026 from $5.5 million at December 31, 2025, despite authorized shares increasing to 567.5 million and multiple equity financings.
Outstanding shares increased to 4.1 million as of September 30, 2026 from 0.6 million at December 31, 2025 following reverse stock split, conversions, and August 2026 Public Offering.
Key metrics
Disclosure changes
- Going concern disclosure
Company concluded there are conditions and events that raise substantial doubt about ability to continue as a going concern within one year after the Condensed Consolidated Financial Statements are issued, based on $5.0 million cash at September 30, 2026, approximately $7.5 million October 2026 Private Placement proceeds, recurring losses and cash outflows, and need to raise substantial additional capital.
Indicates material uncertainty about company's ability to continue operations without additional financing. - Nasdaq continued listing compliance
On November 2, 2026, company received delist determination from Nasdaq for failure to comply with minimum bid price requirement following July 6, 2026 1-for-20 reverse stock split; company appealed and scheduled November 18, 2026 shareholder vote on additional reverse stock split at ratio of 1-for-5 to 1-for-12.
Potential delisting would significantly reduce liquidity and access to capital markets. - Revenue recognition
No revenues reported for Q3 or nine months 2026; company is no longer entitled to Erivedge royalties following November 2025 sale to Oberland.
Company lost its primary revenue stream with the sale of Erivedge; now entirely dependent on emavusertib development. - Warrant liability classification and remeasurement
January 2026 Series A and C Common Warrants initially classified as liabilities ($17.7 million fair value at issuance) due to insufficient authorized shares; reclassified to equity in Q1 2026 after stockholder approval ($28.6 million reclassification) with $14.5 million loss recognized on remeasurement. January 2026 Series B Common Warrants expired unexercised September 28, 2026 with $3.7 million gain on change in fair value.
Complex warrant structures resulted in significant non-cash gains/losses affecting net loss; equity dilution from warrant exercises post-period. - Stockholder equity and authorized shares
Authorized shares increased from 68.3 million to 283.8 million in March 2026 and then to 567.5 million in May 2026. Stockholders' equity declined to $2.6 million despite multiple equity financings due to continued net losses.
Large authorized share increases enable future dilutive financings. - Warrant exercises post-period
Since September 30, 2026: 33,335 shares issued upon exercise of January 2026 Series A Common Warrants, 33,335 shares upon exercise of January 2026 Series C Common Warrants, 920,000 shares upon exercise of August 2026 Pre-Funded Warrants, 1,856,833 shares upon exercise of August 2026 Common Warrants.
Significant additional dilution from warrant exercises post-period.
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow CRIS in real time
Get material earnings, filing, IR, and earnings-call alerts by email.